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Abstract 
Viral infections of the central nervous system (CNS) are underdiagnosed and their etiology often 
unknown.  
To increase case finding and etiologic diagnosis, patients with at least two symptoms among which 
fever, headache, impaired consciousness, focal signs and neck stiffness entered a diagnostic 
algorithm, including risk factors, epidemiological, clinical, laboratoristic and radiological criteria. A 
check list of serologic and molecular virology tests to be performed on blood and cerebrospinal 
fluid was developed. Tests were performed following a priority algorithm.  
The study was conducted in the 2012-2014 period and data were compared with what was found in 
the 2009-2011 period. 
In the 2012-2014 period, 34 cases of suspected viral infection of the CNS were identified. Viral 
etiology was confirmed in 21/34 (61.7%). 
In the 2009-2011 period, 27 cases of suspected viral infection of the CNS were identified. Viral 
etiology was confirmed in 10/27 (37.0%). 
Overall, in the 2009-2014 period, 61 cases have been diagnosed. Males were 34/61 (55.7%), mean 
age was 50.2 (range 18-85). Etiology was established in 31/61 (50.8%) as follows: VZV 9 cases, 
Toscana Virus 6, HSV 1 6, HSV 2 and Enterovirus 3, West Nile 2, HHV 7 and parvovirus B19 one.  
When lumbar puncture was performed within 72h from the onset of symptoms, an etiologic 
diagnosis was made in 15/27 cases (55.5%); when lumbar puncture was performed after 72h from 
the onset of symptoms, an etiologic diagnosis was made in 10/28 cases (35.7%).  
At CSF examination, leukocytes count was increased (>5x10
9
/L) in 59/60 (98.3%) and lymphocytes 
were prevalent in 57/60 (95.0%); glucose was reduced (<50 mg/dl) in 12/60 (20.0%), but 
CSF/blood glucose ratio was less than 40% only in 2/60 (3.3%); proteins were increased (>60 
mg/dl) in 40/60 (66.6%). Overall mean CSF leukocytes count was 280x10
9
/L while mean 
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leukocytes count of Enterovirus infections was 151x10
9
/L and that of VZV infections was 
625x10
9
/L. Mean protein concentration was 110 mg/dl while that of VZV infections was 237.9 
mg/dl. 
Additionally, a seroprevalence survey for Toscana Virus was conducted on consecutive patients 
admitted in the Infectious Diseases Unit, regardless the symptoms: IgG or IgM were positive in 
34/100 cases (34%), with a clear trend to increase with age. 
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Introduction 
An overwhelming number of individuals is affected by different viral infections every day.  
Clinically relevant involvement of the central nervous system (CNS) by viruses is a relatively 
uncommon event, but still represents a significant cause of morbidity and mortality, and a 
phenomenon greatly underestimated and unknown. 
Viral infections of the CNS include a range of different manifestations, most common of which are 
encephalitis, meningitis and myelitis, that however are often concomitant and cannot be easily 
distinguished on a clinical base. 
The spectrum of possible involvements depends on the specific viral agent, host immune status, 
genetic asset and environmental factors.  
In addition, other less established and more unusual manifestations of viral infections include 
progressive neurologic disorders, such as postinfectious encephalomyelitis, like those that may 
occur after measles or Nipah virus encephalitis, and conditions such as postpoliomyelitis syndrome, 
occurring years after acute poliovirus infection. 
Further, vector-transmitted viral infections causing a range of manifestations, including CNS 
involvement, in recent years have been responsible of epidemics in areas where they had never been 
present or had disappeared since decades (emerging and re-emerging infections). 
 
Etiology and epidemiology 
In the United States, more than 10,000 cases of viral meningitis are reported annually, but the actual 
incidence may be as high as 75,000. Lack of reporting is due to the uneventful clinical outcome of 
most cases and the inability of some viral agents to grow in culture. According to reports from the 
Centers for Disease Control and Prevention (CDC), inpatient hospitalizations resulting from viral 
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meningitis range from 25,000-50,000 each year. An incidence of 11 per 100,000 population per 
year has been estimated in some reports. [1] 
The CDC estimate an annual incidence of approximately 20,000 new cases of encephalitis in the 
United States. The annual incidence of viral encephalitis is most likely underestimated, especially in 
developing countries, because of problems with pathogen detection. Japanese Encephalitis affects at 
least 50,000 individuals per year. [2] 
 
Enteroviruses 
Enteroviruses account for the majority of cases of viral meningitis in many casistics. They are part 
of the viral family Picornaviridae ("pico" for small, "rna" for ribonucleic acid). 
Based on their antigenic properties, the original 64 HEV serotypes were initially grouped into 
polioviruses (PV), coxsackieviruses A (CA), coxsackieviruses B (CB), echoviruses (E), and the 
more recently identified enteroviruses (EV) 68 to 71. A new HEV classification based on molecular 
and biological data has recently been proposed as an alternative to the antigenic classification. This 
classification groups enteroviruses into five species: (1) PV, including poliovirus types 1, 2 and 3; 
(2) HEV-A, including 11 coxsackieviruses A and EV71; (3) HEV-B, including all coxsackieviruses 
B, all echoviruses, EV69 and CA9; (4) HEV-C, including 11 other coxsackieviruses A; and (5) 
HEV-D, including EV68 and EV70. The enteroviruses previously classified as E22 and E23, which 
were shown to group independently, now constitute a new genus, Parechovirus (with two 
serotypes), in the family Picornaviridae. [3] 
The overwhelming majority of meningitis cases are caused by serotypes of coxsackievirus and 
echovirus. Coxsackievirus B subgroups alone account for more than 60% of meningitis cases in 
children younger than age 3 months.  
Enteroviruses enter the human host usually via the oral-fecal route, but can also spread through the 
respiratory route. 
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Enteroviruses are ubiquitous in the summer and early fall; their propensity to cause infection during 
the warmer months is the major factor in the higher incidence of aseptic meningitis during that time.  
The associated clinical findings in enteroviral infections may include pharyngitis, pleurodynia, rash, 
and pericarditis. 
Expectant mothers infected with coxsackievirus B may remain minimally symptomatic, but their 
infants can acquire the infection perinatally and develop a potentially fatal illness, with the infection 
targeted mainly toward the heart.  
Enteroviruses 70 and 71, which exhibit strong neurotropism, are associated with 
meningoencephalitis, poliolike paralytic syndromes, and Guillain-Barre syndrome, as well as 
aseptic meningitis. 
 
Arboviruses 
Arboviruses account for about 5% of cases of meningitis in North America. 
Arboviruses consist of more than 500 viruses from different viral families, all given the common 
name "ar-bo," for arthropod-borne disease (table 1). 
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Blood-sucking arthropods, usually mosquitoes, serve as vectors for transmission. Because exposure 
to mosquitoes or ticks is the risk factor for transmission, the number of infections is highest in 
summer and early fall, consistently with high mosquito populations.  
Some of the important arboviruses include the eastern and western equine encephalitis viruses, from 
the Togavirus family; St. Louis encephalitis, West Nile, Japanese B, and Murray Valley viruses, 
from the Flavivirus family; California group and Jamestown Canyon viruses, from the Bunyaviridae 
family. Colorado tick fever is caused by a coltivirus in the western regions of the United States.  
The most common clinical manifestation is meningoencephalitis rather than pure meningitis. 
Seizures are more common with arboviral meningitis than with any other group of viruses. 
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Some agents preferentially infect certain age groups, such as St. Louis encephalitis, which affects 
the extremes of age, and California virus, which infects young children. Children with St. Louis or 
California group encephalitis viruses may not exhibit any neurologic signs or altered mental status.  
St. Louis encephalitis (SLE) virus is the most common cause of arboviral meningitis, and is also the 
most common mosquito-transmitted disease in the United States.  
Japanese B encephalitis virus, the most common pathogen in epidemic viral meningitis worldwide, 
accounts for more than 35,000 infections annually throughout Asia but is estimated to cause 200-
300 times that number of subclinical infections. 
Of the arboviruses, West Nile virus caused much attention, as it was first recognized in the United 
States only in 1999 and quickly became an epidemic in 2002, with more than 4,000 reported cases. 
In 2008, 1,356 cases were reported.[4]  
Infection with the West Nile virus is usually asymptomatic or manifests as mild symptoms of 
nonspecific fever, myalgia, and fatigue. However, 1 in 150 cases develops into severe disease 
involving the nervous system, with encephalitis reported more than meningitis. In 2008, 687 cases 
of West Nile neuroinvasive disease were reported to the US Centers for Disease Control and 
Prevention (CDC) from all across the United States.[4]  
Neuroinvasive West Nile disease occurs more often in elderly persons. 
 
Toscana Virus 
Toscana virus (TOSV) is an arthropod-borne virus, identified in 1971, from Phlebotomus 
perniciosus and Phlebotomus perfiliewi in central Italy. TOSV belongs to the Phlebovirus genus 
within the Bunyaviridae family. As other bunyaviruses, the genome of TOSV consists of 3 
segments (S for small, M for Medium, and L for Large) respectively encoding non structural and 
capsid proteins, envelope structural proteins, and the viral RNA-dependant RNA-polymerase. It is 
transmitted by sand flies. Therefore its distribution is bound to that of the arthropod vectors, and 
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virus circulation peaks during summertime when sandfly populations are active. The first evidence 
of its pathogenicity in humans, specifically its propensity to cause central nervous system (CNS) 
infections such as meningitis and encephalitis, was reported in central Italy. Only after 2000, it was 
recognized that TOSV had a much larger geographic distribution than initially believed, and was 
present in most of the Western European countries located on the northern border of the 
Mediterranean Sea (Portugal, Spain, France, Greece, Croatia) as well as eastern countries such as 
Cyprus and Turkey. In the countries where TOSV is present, it is among the three most prevalent 
viruses in meningitis during the warm seasons, together with enteroviruses and herpesviruses. Up to 
now, epidemiological data concerning Northern Africa and other countries located south of the 
Mediterranean are scarce. TOSV must be considered an emerging pathogen. Despite the important 
role played by TOSV in CNS infections, it remains a neglected agent and is rarely considered by 
physicians in diagnostic algorithms of CNS infections and febrile illness during the warm season, 
probably because of the lack of information.[5] 
 
 
 
Adapted from Depaquit J et al, Eurosurveillance, Volume 15, Issue 10, 11 March 2010 
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Mumps 
A member of the Paramyxoviridae family, mumps virus was one of the first known causative 
agents of meningitis and meningoencephalitis.[6]  
The incidence of mumps in the vaccination era has decreased significantly to 1 per 100,000 
population in the United States. 
Nonetheless, outbreaks have occurred in vaccinated populations, including a large epidemic in the 
United Kingdom that peaked in 2005 and several outbreaks in the American Midwest in 2006.[7] In 
addition, mumps continues to cause 10-20% of meningitis and meningoencephalitis cases in parts of 
the world where vaccines are not readily accessible.  
Males 16-21 years of age are at highest risk for developing this infection, with a 3:1 male/female 
ratio. 
Clusters of cases occur in schools and colleges in the winter months. 
Concomitant parotitis is a helpful clinical tool, but it may be absent in as many as half of cases with 
CNS involvement. 
A cohort study of 12,000 unvaccinated children from northern Finland revealed that mumps 
meningoencephalitis accounted for 40.9% of all viral CNS infections. Mumps also remains an 
important cause of aseptic meningitis in England and Japan.  
In 2003, epidemics of aseptic meningitis following measles, mumps, rubella (MMR) vaccination 
campaigns in various nations (including Brazil and the UK) prompted the Global Advisory 
Committee on Vaccine Safety to conduct a review of vaccine-derived mumps meningitis.[8] At the 
time, the committee stated that certain strains of the mumps vaccine (Urabe, Leningrad-Zagreb, and 
Leningrad-3 strains) were associated with higher incidences of postvaccination aseptic meningitis. 
In 2006, the committee determined that the international literature reviewed was actually 
inconclusive and that further studies were needed.[9] Even so, replacement mumps components 
were developed and vaccines were reformulated worldwide.  
14 
 
Herpes family viruses 
Herpes simplex virus HSV-1, HSV-2, varicella-zoster virus (VZV), Ebstein-Barr virus (EBV), 
cytomegalovirus (CMV), and human herpesvirus-6 (HHV-6) collectively cause approximately 4% 
of cases of viral meningitis, with HSV-2 being the most common offender. The viruses may attack 
at any time of the year.  
Meningitis caused by these viruses is often self-limited. When associated with encephalitis, 
however, the mortality rate can be high. Early treatment with acyclovir can significantly reduce 
morbidity.  
HSV-1 remains the most common cause of sporadic encephalitis, while HSV-2 infections of CNS 
mostly are restricted to aseptic meningitis.  
HSV-2 genital infection may precede meningitis; sexual contact with actively infected individuals is 
one of the known risk factors.  
In one review, however, only 3 of 23 patients with HSV-2 meningitis had a history of prior genital 
herpes or had genital lesions noted at the time of presentation.[10] Maternal-fetal transmission of 
HSV-2 can occur, leading to significant systemic sequelae, including infantile septicemia and death.  
EBV, HSV-1, and especially HSV-2 have been associated with Mollaret meningitis, a rare, benign, 
recurrent meningitis that resolves spontaneously. Mollaret cells (activated monocytes with an 
atypical appearance of enlarged, bilobed nuclei and amorphous cytoplasm) are found in the CSF 
usually on the first day of symptoms. HHV-6, EBV, and the human immunodeficiency virus (HIV) 
have also been implicated. These viruses are all known to remain latent within the nervous system. 
CMV infections occur mostly in immunocompromised hosts. CMV may cause subacute 
encephalitis in patients with AIDS. Congenital CMV, which is a much more serious form of 
infection, has significant associated morbidity and mortality.  
Childhood or adult chickenpox infections by VZV rarely are complicated by meningitis. Adult 
zoster involving any dermatome may lead to meningitis or meningoencephalitis. 
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Lymphocytic choriomeningitis virus 
LCMV belongs to the family of arenaviruses. Now a rare cause of meningitis, the virus is 
transmitted to humans by contact with rodents (eg, hamster, rats, mice) or their excreta. Persons at 
highest risk of infection are laboratory workers, pet owners, or persons living in nonhygienic areas.  
 
Adenovirus 
Adenovirus is a rare cause of meningitis in immunocompetent individuals but a major cause in 
patients with acquired immunodeficiency syndrome (AIDS). The infection may occur 
simultaneously with an upper respiratory infection.  
 
Measles 
This Morbillivirus is another cause of meningitis that has become rare. The characteristic 
maculopapular rash aids in the diagnosis. Most cases occur in younger people in schools and 
colleges. Still a worldwide health threat, measles has the highest attack rate of any infection. 
Eradication of measles is an important goal of the World Health Organization (WHO). 
 
HIV 
HIV may be a cause of atypical meningitis characterized by chronicity and recurrence. About the 
time of seroconversion, patients may present with CSF pleocytosis, elevated protein level and, 
occasionally, high intracranial pressure.  
Reports have suggested that as many as 5-10% of HIV infections can be heralded by meningitis. 
Aside from the usual meningeal signs, HIV infections may also cause global encephalopathy, 
seizures, and focal neurologic deficits. Some patients develop chronically abnormal CSF findings 
with mild or no symptoms. HIV often can be isolated from the CSF.  
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Pathophysiology and clinical manifestations 
Viral pathogens may gain access to the CNS via either of two main routes: hematogenous and 
neural. The hematogenous route is more common for penetration of most known viral pathogens. 
Neural penetration refers to spread along nerve roots and is usually limited to herpes viruses (HSV-
1, HSV-2, VZV) and possibly some enteroviruses.  
Multiple host defenses prevent viral inoculum from causing clinically significant infection. These 
include local and systemic immune responses, skin and mucosal barriers, and the blood-brain 
barrier (BBB).  
The virus replicates in the portal of entry (ie, respiratory or gastrointestinal mucosa) and gains 
access to the bloodstream. Primary viremia introduces the virus to the reticuloendothelial organs 
(liver, spleen, lymph nodes). If the replication persists despite immunologic defenses, secondary 
viremia occurs, which is thought to be responsible for seeding of the CNS. Rapid viral replication 
likely plays a major role in overcoming the host defenses.  
The actual mechanism of viral penetration into the CNS is not well understood. The virus may cross 
the BBB directly at the capillary endothelial level or through natural defects, such as the area 
postrema and other sites that lack a BBB.  
The inflammatory response is seen in the form of pleocytosis; polymorphonuclear leukocytes 
(PMNs) lead the differential cell count in the first 24-48 hours, followed later by increasing 
numbers of monocytes and lymphocytes. The CSF lymphocytes have been recognized as T cells, 
although B cell immunity is also important in defending against some viruses.  
Evidence exists that some viruses gain access to the CNS by retrograde transport along nerve roots. 
For example, the likely pathway for HSV-1 encephalitis is via the olfactory or trigeminal nerve 
roots, with the virus being transported by the olfactory fibers to the basal frontal and anterior 
temporal lobes.  
17 
 
Upon presentation, most patients report fever, headache, irritability, nausea, vomiting, stiff neck, 
rash, or fatigue within the previous 18-36 hours. Constitutional symptoms of vomiting, diarrhea, 
cough, and myalgias appear in more than 50% of patients.  
For several weeks or longer, children may experience irritability, incoordination, and an inability to 
concentrate. 
Headache is almost always present in patients with viral meningitis and is often reported as severe. 
However, the classic description of abrupt onset of the "worst headache of my life," attributable to 
aneurysmal subarachnoid hemorrhage, is uncommon.  
History of temperature elevation occurs in 76-100% of patients who come to medical attention. A 
common pattern is low-grade fever in the prodromal stage and higher temperature elevations at the 
onset of neurological signs.  
Younger children may not report headache and may simply be irritable. 
Newborns may present with poor feeding and lethargy. 
Some viruses cause rapid onset of the above symptoms, while others manifest as nonspecific viral 
prodromes, such as malaise, myalgia, and upper respiratory symptoms. In many cases, symptoms 
have a biphasic pattern; the nonspecific flu-like symptoms and low-grade fever precede neurologic 
symptoms by approximately 48 hours. With the onset of neck stiffness and headache, the fever 
usually returns.  
Meticulous history taking is essential and must include evaluation of exposure to ill contacts, 
mosquitoes, ticks, outdoor activity in areas of endemic Lyme disease, travel history with possible 
exposure to tuberculosis, as well as history of medication use, intravenous drug use, and sexually 
transmitted disease risk.  
Some general physical findings in viral meningitis are common to all causative agents.  
The classically taught triad of meningitis consists of fever, nuchal rigidity, and altered mental 
status, but not all patients have all 3 symptoms.  
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Fever is common (80-100% of cases) and usually ranges from 38°-40°C. 
Neck stiffness or other signs of meningeal irritation (Brudzinski or Kernig sign) may be seen in 
more than half of patients, but these symptoms are generally less severe than they are in bacterial 
meningitis. Pediatric patients, especially neonates, tend not to exhibit nuchal rigidity on 
examination.  
Irritability, disorientation, and altered mentation may be seen. 
Severe lethargy or bulging fontanelle in neonates is a sign of increased intracranial pressure but 
may be absent in more than half of all cases. The neonate may exhibit hypotonia, irritability, and 
poor feeding. The clinical picture can mimic neonatal bacterial septicemia accompanied by multiple 
organ system involvement.  
Headache is common and is characteristically severe. 
Photophobia is relatively common but may be mild. Phonophobia may also be present. 
Seizures occur occasionally and are usually a result of the fever, although the involvement of brain 
parenchyma (encephalitis) should be considered.  
Global encephalopathy and focal neurologic deficits are rare but can be present. Deep tendon 
reflexes are usually normal but may be brisk.  
Various signs of specific viral infection can aid in diagnosis. These include the following: 
 Pharyngitis and pleurodynia in enteroviral infections 
 Skin manifestations, such as zoster eruption from VZV, maculopapular rash from measles 
and enteroviruses, vesicular eruption from herpes simplex, and herpangina from 
coxsackievirus A infections  
 Pharyngitis, lymphadenopathy, and splenomegaly, which suggest EBV infection 
 Immunodeficiency and pneumonia, which should suggest adenovirus, CMV, or HIV as the 
causative agent 
 Parotitis and orchitis, from mumps 
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 Gastroenteritis and rash, which occur with most enteroviral infections 
The prognosis for viral meningitis is usually excellent, with most cases resolving in 7-10 days. 
Implicit in the diagnosis is the self-limited nature of this disease. The exception falls with the 
neonatal patients, in whom viral meningitis can be fatal or associated with significant morbidity.  
Concomitant encephalitis adds significant potential for adverse outcomes. Concurrent systemic 
manifestations, such as pericarditis and hepatitis, are other indicators of poor prognosis. 
 
Diagnosis 
General assessment 
Routine chemistry and hematology tests, arterial blood gas analysis, coagulation studies, and liver 
function tests should be performed.  
The serum white blood cell (WBC) count is not a sensitive indicator of the severity of infection, 
especially in the immunocompromised, neonatal, or elderly patient. However, a high WBC, 
particularly neutrophils, suggest a bacterial etiology. 
The serum sodium level may be abnormal because of dehydration or the rare occurrence of 
syndrome of inappropriate antidiuretic hormone secretion (SIADH). Since abnormal sodium levels 
may contribute to neurological symptoms, these must be followed up and if needed corrected. 
The serum amylase level may be elevated in cases of viral meningitis that are caused by mumps, 
even in the absence of parotitis. 
Reports have shown high C-reactive protein (CRP) levels in the serum of children with bacterial 
meningitis whose CSF Gram stain findings were negative for bacteria. However, a comparable 
group of children with viral meningitis did not have similar elevations in serum CRP (ie, 50-150 in 
bacterial meningitis group vs < 20 in the viral meningitis group).  
Microscopy of CSF should be performed to better define the nature of white cells and detect 
bacteria and fungi. 
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All patients whose condition is not improving clinically within 24-48 hours should have a more 
extensive workup to discern the cause of meningitis.  
 
Cerebrospinal fluid examination 
CSF examination is the most important test in establishing the cause of meningitis. Prior to lumbar 
puncture (LP), a computed tomography (CT) scan should be performed in patients with any 
abnormal neurologic sign, to exclude an intracranial lesion or obstructive hydrocephalus. 
A high WBC count in the CSF (especially neutrophils), a high protein level, and a low glucose level 
should suggest a diagnosis of a bacterial meningitis, although some viral pathogens may produce 
similar CSF profiles. In fact, pleocytosis with WBC counts in the range of 50 to more than 1,000 x 
10
9
/L of blood has been reported in viral meningitis. Mononuclear cell predominance is the rule, but 
PMNs may make up most cells in the first 12-24 hours; the cell count is usually then dominated by 
lymphocytes in the classic CSF pattern of viral meningitis. This helps to distinguish viral from 
bacterial meningitis, which has a much higher cell count and a predominance of PMNs in the cell 
differential, although this is not an absolute rule. In fact, a retrospective multicenter study found that 
neither the presence nor quantity of immature neutrophils (bands) in CSF independently predicted 
bacterial meningitis among children with CSF pleocytosis.[11]  
The CSF protein level usually is only slightly elevated, but it can range from normal to as high as 
200 mg/dL. 
The glucose level is normal in most cases, but severe hypoglycorrhachia has been reported, 
especially with LCMV or the mumps virus. Very low glucose levels with a lymphocytic pleocytosis 
may be seen in tuberculous meningitis.  
 
Etiologic diagnosis 
Blood, feces, and throat swabs need be sent for viral serology and cultures. 
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Serum titers of antibodies against possible etiologic infective agents should be obtained at 
admission. Additional serum collection 10-21 days later may aid in discerning rising titers in the 
antibodies against specific viral pathogens; a 4-fold increase in viral antibodies confirms the 
diagnosis. This is particularly useful for arboviral and LCMV cases, but it also is helpful in ruling 
out toxoplasmosis, leptospirosis, borreliosis, and rickettsial infections. Although some of these 
studies do not yield an immediate result for clinical decision making, they may be useful for 
prognostication.  
Real-time PCR testing for enterovirus was first cleared for marketing in 2007 by the US Food and 
Drug Administration (FDA) and is now available through commercial laboratories.[10] Results are 
available in approximately 3 hours, as opposed to days to weeks in traditional PCR studies. In 
clearing the test, the FDA cited a multicenter study in which 96% of patients who tested positive did 
have viral meningitis, and 97% of patients who tested negative did not have viral meningitis.  In a 
retrospective study of routine PCR testing of CSF for enterovirus—using a test with turnaround 
time of 23 hours—confirmation of enteroviral meningitis by PCR decreased the length of 
hospitalization and the duration of antibiotic use among infants aged 90 days or younger.[13] 
Among 22 children with meningitis due Enterovirus, in 10 patients, genome was detected in CSF 
only; in 3 patients in serum only, and in 9 patients in both. Therefore, the test on CSF seems to be 
much more sensitive, but the test on serum might detect an additional small group of cases. [14] 
In recent years, PCR on CSF has become the gold standard for the diagnosis of viral infections of 
the CNS. Rapid viral clearance was typical for HSV, VZV, CMV, and EV infections, although the 
maximum duration of viral detection was 15days for HSV and 12days for VZV, respectively. This 
suggests that the detection of HSV, VZV, CMV, and EV strongly indicates symptomatic viral CNS 
disease. [15] 
If the results of PCR testing of the CSF and the viral culture for herpes simplex are negative, 
acyclovir can be discontinued; otherwise, a 10-day course is recommended. 
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Imaging 
In patients in whom encephalitis is suspected, MRI with contrast enhancement and adequate 
visualization of the frontal and temporal areas, typically affected by HSV, is necessary. 
Electroencephalography (EEG) may be performed if encephalitis or subclinical seizures are 
suspected in the altered patient. Periodic lateralized epileptiform discharges (PLEDs) are often seen 
in herpetic encephalitis.  
 
Treatment 
Treatment for viral meningitis is mostly supportive. Rest, hydration, antipyretics, and pain or anti-
inflammatory medications may be given as needed. The most important decision is whether to 
initiate antimicrobial therapy empirically for bacterial meningitis while waiting for the cause to be 
identified. Intravenous (IV) antibiotics should be administered promptly if bacterial meningitis is 
suspected.  
No surgical therapy is usually indicated in patients with viral meningitis. In rare patients in whom 
viral meningitis is complicated by hydrocephalus, a CSF diversion procedure, such as 
ventriculoperitoneal (VP) or LP shunting, may be required. Ventriculostomy with an external 
collection system is indicated in the rare cases of acute hydrocephalus.  
Patients with signs and symptoms of meningoencephalitis should receive acyclovir early to possibly 
curtail HSV encephalitis. Therapy can be modified as the results of Gram stain, cultures, and PCR 
testing become available. Patients in unstable condition need critical care unit admission for airway 
protection, neurologic checks, and the prevention of secondary complications.  
Enteroviruses and HSV are each capable of causing viral septic shock in newborns and infants. In 
these young patients, broad-spectrum antibacterial coverage and acyclovir should be instituted as 
soon as the diagnosis is suspected. Special attention should be paid to fluid and electrolyte balance 
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(especially sodium), since SIADH has been reported. Fluid restriction, diuretics, and, rarely, 
hypertonic saline infusion may be used to correct the hyponatremia. Prevention of secondary 
infections of urinary tract and pulmonary systems is of paramount importance.  
Waiting for LP results should not delay administration of antibiotics when warranted on clinical 
grounds. Broad-spectrum coverage is attained with ampicillin and a third-generation cephalosporin 
(ceftriaxone or cefotaxime; ceftazidime can also be used). Aminoglycosides are used in severe 
infections in neonates or children. Antituberculous, antifungal, and antiretroviral medications are 
reserved for clinically suggested or laboratory-confirmed cases.  
Seizures should be treated immediately with IV anticonvulsants, such as lorazepam, phenytoin, 
midazolam, or a barbiturate. Unconscious patients with viral encephalitis may be in nonconvulsive 
status epilepticus, and EEG is used to reveal and monitor subclinical seizures.  
Cerebral edema does occur in cases of severe encephalitis and may require intracranial pressure 
control by infusion of mannitol, IV dexamethasone, or intubation and mild hyperventilation, with 
arterial PCO2 around 28-30 mm Hg. Placement of an intracranial pressure monitor with transduced 
intraparenchymal pressure is recommended in these cases.  
Multiple antiviral medications are currently being tested in the general population; their impact on 
preventing the sequelae of viral meningitis and encephalitis has not yet been established. In herpetic 
viral infections, acyclovir is significantly beneficial only if given very early in the course of the 
infection. Suspected cases should be treated as soon as possible; in cases complicated by seizures, 
encephalitis is assumed and acyclovir should be initiated.  
Ganciclovir is used for severe CMV-related infections such as congenital infection or infection in 
immunocompromised hosts, including hematologic patients and transplant recipients.  
Administration of IVIg to neonates with overwhelming enteroviral meningitis has met with 
occasional success and is reserved for severe cases lacking other therapeutic options.  
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Objectives 
The main aim of this study was to validate a diagnostic protocol in order to increase the detection of 
cases of viral infections of the CNS and the proportion of cases with an etiologic diagnosis.  
Secondarily, we also aimed at characterizing viral strains, particularly those of emerging diseases, 
such as dengue fever virus, West Nile virus and Toscana virus, correlating them with epidemiology, 
clinical and immunological features. 
 
Methods 
Patients referred to Emergency Department and the Infectious Diseases Unit of the Azienda 
Ospedaliera Universitaria Pisana were screened. Patients with at least two symptoms among which 
fever, headache, impaired consciousness, focal signs and neck stiffness entered the diagnostic 
algorithm. 
The diagnostic algorithm was developed including risk factors, epidemiological, clinical, 
laboratoristic and radiological criteria, on the basis of the existing literature (Figure 2). 
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Figure 2. Diagnostic algorithm for the diagnosis of Central Nervous System infections 
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Patients were classified as having meningitis if they had neck stiffness, other signs of meningeal 
irritation or laboratory evidence of inflammation at CSF examination, encephalitis if they had focal 
signs, impaired consciousness or seizures, meningoencephalitis if they had both. 
A check list of serologic and molecular virology and microbiology tests to be performed on blood 
and cerebrospinal fluid of patients with aseptic infection of the CNS was developed and distributed 
to the Infectious Diseases clinicians (Figure 3). 
Figure 3. Check List for the etiologic diagnosis of aseptic infection of the Central Nervous 
System infections 
TESTS ON SERUM 
Antibodies 
□ Widal-Wright 
□ Listeria monocytogenes 
□ Borrelia burgdorferi 
□ Leptospira spp 
□ Mycoplasma pneumonia 
□ Chlamydia pneumonia 
□ Coxiella burnetii 
□ Bartonella henselae 
□ Rickettsia conori 
□ Rickettsia typhi 
□ lue screening 
□ Toscana virus 
□ HSV 1 and 2, VZV, CMV, EBV, HHV 6, HHV 7 
□ Coxsackie virus, Echovirus, 
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□ Adenovirus 
□ HIV 
□ West Nile 
□ Tick Born Encephalitis (TBE) 
□ Lymphocitic Choriomeningitis Virus (LCMV) 
□ Parotitis 
□ Rubella 
□ Parvovirus B19 
□ HTLV I/II 
□Chikungunya 
□ Quantiferon 
□ Cryptococcus antigen 
 
TESTS ON CSF 
□ Physical-chemical analysis 
□ Culture and methilene blue stain 
Genomes 
□ HSV 1 and 2, VZV, CMV, EBV, HHV 6, HHV 7 
□ Enterovirus 
□ Adenovirus 
□ Human Respiratory Syncytial Virus 
□ HIV 
□ West Nile 
□ Chikungunya 
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□ Parvovirus B19 
Antibodies 
□ Borrelia burgdorferi 
□ Toscana virus 
□ HSV 1 and 2, VZV, CMV, EBV, HHV 6, HHV 7 
□ Coxsackie virus, Echovirus 
□ Adenovirus 
□ HIV 
□ West Nile 
□ TBE 
□ LCMV 
□ Parotitis 
□ Rubella 
□ Parvovirus B19 
□ HTLV I/II 
□ Chikungunya 
□ PCR, culture and ZN stain for mycobacteria 
□ Cryptococcus antigen 
 
OPTIONAL 
□ Influenza genome on pharingeal and nasal swab during epidemic season 
□ Complete syphilis  serology on serum and CSF in case of positive screening or 
HIV positive patient 
□ HSV 1 and 2 or VZV genome on vesicular cutaneous lesions 
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□ JC genome in CSF of immunocompromised patients 
□ Toxoplasma serology on serum and genome in CSF of immunocompromised 
patients with focal lesions 
□ Serology of Dengue and other Arbovirus based on epidemiology 
□ Genome, culture and ZN stain on sample other than CSF 
□ Incomplete antibodies for Brucella 
Samples have been processed at the laboratory of the Division of Virology of the Azienda 
Ospedaliera Universitaria Pisana. Tests were performed following a priority algorithm. 
Comprehensive biochemical and immunological tests, including lymphocyte subpopulation 
analysis, protein electrophoresis and immunoglobulin subclasses determination, were performed. 
Neuroimaging procedures were conducted according to the diagnostic algorithm and in case other 
clinical indications existed. 
Epidemiological, laboratory and clinical data were collected using a specifically designed, 
dedicated database.  
Patients were followed up for at least 6 months. 
Samples of blood and cerebrospinal fluid were stored at -80°C. 
The same data were retrospectively analyzed for the cases diagnosed in the 2009-2011 period. 
Additionally, a seroprevalence survey for Toscana Virus was conducted on consecutive patients 
admitted in the Infectious Diseases Unit at admission, regardless the symptoms. 
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Results 
In the 2012-2014 period, 34 cases of suspected viral infection of the CNS were identified. Males 
were 23/34 (67.6%), mean age was 51.7 (range 25-84). Viral etiology was confirmed in 21/34 
(61.7%): VZV in 8 cases, Toscana Virus in 4 cases, West Nile, Enterovirus and HSV 1in 2 cases, 
HSV 2, HHV 7 and parvovirus B19 in one case. 
In the 2009-2011 period, 27 cases of suspected viral infection of the CNS were identified. Males 
were 11/27 (40.7%), mean age was 48.5 (range 18-85). Viral etiology was confirmed in 10/27 
(37.0%): HSV 1 in 4 cases, HSV 2 in 2 cases, Toscana Virus in 2 cases, VZV and Enterovirus in 
one case. 
Overall, in the 2009-2014 period, 61 cases have been diagnosed. Males were 34/61 (55.7%), mean 
age was 50.2 (range 18-85). Age distribution is reported in figure 4.  
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Figure 4. Age distribution of patient with viral infection of the Central Nervous System, Pisa, 
2009-2014 
 
 
Etiology was established in 31/61 (50.8%) as follows: VZV 9 cases, Toscana Virus 6, HSV 1 6, 
HSV 2 and Enterovirus 3, West Nile 2, HHV 7 and parvovirus B19 one (table 1).  
When lumbar puncture was performed within 72h from the onset of symptoms, an etiologic 
diagnosis was made in 15/27 cases (55.5%); when lumbar puncture was performed beyond 72h 
from the onset of symptoms, an etiologic diagnosis was made in 10/28 cases (35.7%).  
In case of VZV, PCR on CSF was positive in 6/9 cases; in 6 cases, including those with negative 
PCR on CSF, CNS involvement occurred in association with varicella or zoster and PCR from 
vesicles was positive in all cases. In case of HSV-1, PCR on CSF was positive in 5/6 cases; in that 
with negative result, PCR was positive on serum. In case of HSV-2, PCR on CSF was positive in 
2/3 cases; in that with negative result, PCR was positive on serum. In 6/6 cases of Toscana virus 
infection, diagnosis was based on detection of IgM on serum; IgM on CSF were also detected in 3/4 
cases; in one case PCR on CSF was also performed and turned negative. In case of Enterovirus, 
PCR on CSF was positive in one case and neutralizing antibodies at high titer positive in the 
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remaining two cases. In case of West Nile virus, diagnosis was based on detection of IgM on serum. 
In case of HHV-7, PCR was positive on CSF. In case of parvovirus B19, PCR was positive on CSF. 
 
Table 1. Etiology of viral infections of the Central Nervous System, Pisa, 2009-2014 
Etiology N % 
Varicella Zoster Virus 9/61 14.7 
Herpes simplex Virus 1 6/61 9.8 
Toscana Virus 6/61 9.8 
Herpes Simplex Virus 2 3/61 4.9 
Enterovirus 3/61 4.9 
West Nile Virus 2/61 3.2 
Parvovirus B19 1/61 1.6 
Human Herpes Virus 7 1/61 1.6 
Unknown 28/61 45.9 
 
Clinical classification was as follows: 32 patients had meningitis, 25 had meningoencephalitis, 2 
had myelitis, one had meningoencephalomyelitis, one had meningoradiculoneuritis (table 2). 
Among patients with meningitis, 4 had a Toscana virus infection, 3 had a HSV-2 infection, 
including one case of relapsing HSV-2 meningitis, namely Mollaret syndrome, 1 had Enterovirus, 1 
HHV-7, 1 West Nile virus, 1 parvovirus B19, 21 an infection of unknown etiology. Among patients 
with meningoencephalitis or meningoencephalomyelitis, 8 had VZV infection, 3 HSV-1, 2 Toscana 
virus, 1 Enterovirus,10 an infection of unknown etiology. One patient with meningoradiculoneuritis 
had VZV infection and one patient with myelitis West Nile Infection. 
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Table 2. Clinical classification of viral infections of the Central Nervous System, Pisa, 2009-
2014 
Clinical classification N % 
Meningitis 31/61 50.8 
Meningoencephalitis 25/61 41.0 
Myelitis 2/61 3.3 
Meningoencephalomyelitis 1/61 1.6 
Meningoradiculoneuritis 1/61 1.6 
 
Mean length of stay was 11.9 days.  
All patients lived in the catchment area of the Hospital, apart one tourist from Belgium. 
Impaired immunity was detected in 14 cases: diabetes in 3 cases, malignancy, renal failure and 
immunosuppressive therapy in 2 cases, HIV and splenectomy, alcoholism, 
hypogammaglobulinemia, idiopathic CD4 lymphocyte reduction in one case (table 3). Among the 
14 patients with some kind of immunosuppression, 6 case had VZV infection, 3 HSV-1 infection, 
one Toscana virus infection and 3 infection of unknown etiology. 
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Table 3. Demography and comorbidities of patients with viral infections of the  
Central Nervous System, Pisa, 2009-2014 
 N % 
Males/females 34/60 56.7/42.3 
Mean age 50.4 (25-85)  
Immunosuppresive condition   
  Diabetes 3/61 4.9 
  Immunosuppressive treatment 2/61 3.2 
  Malignancy 2/61 3.2 
  HIV 1/61 1.6 
  Hypogammaglobulinemia 1/61 1.6 
  Alcohol abuse 1/61 1.6 
  Renal failure 2/61 3.2 
  Asplenism 1/61 1.6 
  Idiopathic CD4 deficit 1/61 1.6 
Other comorbidities   
  Migraine/recurrent headache 8/61 13.1 
  Chronic Cerebral Ischemia 4/61 6.5 
  Hypertension 9/61 14.8 
  Body weight excess/Obesity 4/61 6.5 
  Rheumatoid arthritis 2/61 3.2 
  Atopic dermatitis 1/61 1.6 
 
At least two among fever, headache, impaired consciousness, focal signs and neck stiffness were 
present at admission  in all patients but two, one with West Nile myelitis and one with VZV 
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meningoencephalitis and zoster. In particular, fever occurred in 54/61 (88.5%), headache in 42/61 
(68.9%), neck stiffness in 35/61 (57.4%), impaired consciousness in 24/61 (39.3%), seizures in 8/61 
(13.1%), focal signs in 4/61 (5.0%) (table 4). 
 
Table 4. Clinical features of viral infections of the Central Nervous System, Pisa, 2009-2014 
Clinical manifestation N % 
Fever 54/61 88.5 
Headache 42/61 68.9 
Neck stiffness 35/61 57.4 
Impaired consciousness 24/61 39.3 
Seizures 8/61 13.1 
Focal signs 4/61 6.6 
 
Plain CT scan was negative in all cases but one case of HSV-1 encephalitis who showed a 
hypodensity in the temporal lobe and finally died. Magnetic resonance showed findings consistent 
with infection in 12/28 (42.8%); signs of cerebral parenchymal involvement were found in 6/27 
(22.2%) cases of meningoencephalitis, 5 due to HSV-1 and one due to VZV. 
EEG revealed abnormalities in 34/51 (66.7%)(table 5). Localized abnormalities were found in 20/27 
(74.1%) cases of meningoencephalitis or meningoencephalomyelitis. 
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Table 5. Sensitivity of imaging and EEG in the diagnosis of viral infections of the Central 
Nervous System, Pisa, 2009-2014 
Method Abnormalities 
N % 
Plain CT scan 1/56 1.8 
Magnetic Resonance 12/28 42.8 
EEG 34/51 66.7 
 
At admission, C-reactive protein was altered (>0.5 mg/dl) in 36/57 (63.5%); procalcitonin was 
slightly above normality (>0.5 mg/dl) in 2/36 (5.5%) cases: one VZV encephalitis and one Toscana 
virus meningitis. WBC was increased (>11,000x10
9
/L) in 21/61 (34.4%); an increase in the 
neutrophil count (>7,500x10
9
/L) was observed in 20/61 (32.8%), an increase in the lymphocyte 
count (>3,500x10
9
/L) was observed in 1/61 (1.6%). 
In 7/54 (13.0%) patients a reduced absolute count of CD4 lymphocytes (<410x10
9
/L) was detected; 
in 7/54 (13.0%) patients a reduced absolute count of CD8 lymphocytes (<190x10
9
/L); in 7/54 
(13.0%) patients a reduced absolute count of NK lymphocytes (<90x10
9
/L). 
Only 4/50 (8.0%) patients had a reduced level of IgG (<700 mg/dl), none had a reduced level of 
IgA or IgM. 
C3c was slightly below normal (90 mg/dl) in 2/17 (11.7%) cases; C4 was slightly below normal (10 
mg/dl) in 2/17 (11.7%) cases s well (table 6). 
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Table 6. Laboratory features of viral infections of the Central Nervous System, Pisa, 2009-
2014 
Parameter N % 
C reactive protein increase 36/57 63.5 
Procalcitonin increase 2/36 5.5 
WBC increase 21/61 34.4 
Neutrophils increase 20/61 32.8 
CD4+ lymphocyte decrease 7/54 13.0 
CD8+ lymphocyte decrease 7/54 13.0 
NK lymphocyte decrease 7/54 13.0 
IgG decrease 4/50 8.0 
C3c decrease 2/16 12.5 
C4 decrease 2/16 12.5 
 
At CSF examination, leukocytes count was increased (>5x10
9
/L) in 59/60 (98.3%) and lymphocytes 
were prevalent in 57/60 (95.0%); glucose was reduced (<50 mg/dl) in 12/60 (20.0%), but 
CSF/blood glucose ratio was less than 40% only in 2/60 (3.3%); proteins were increased (>60 
mg/dl) in 40/60 (66.6%) (table 7). Overall mean CSF leukocytes count was 280x10
9
/L while mean 
leukocytes count of Enterovirus infections was 151x10
9
/L and that of VZV infections was 
625x10
9
/L. Mean protein concentration was 110 mg/dl while that of VZV infections was 237.9 
mg/dl. 
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Tale 7. Cerebrospinal fluid features of viral infections of the Central Nervous System, Pisa, 
2009-2014 
Feature N % 
WBC count increase 59/60 98.3 
Glucose decrease 12/60 20.0 
CSF/Blood glucose ratio decrease 2/60 3.3 
Proteins increase 40/60 66.6 
 
Acyclovir was administered empirically in all cases and discontinued in case HSV genome on CSF 
was negative. Steroids were administered in 4 cases. Outcome was favorable in all but 5 cases: two 
died and three had permanent consequences, namely paraparesis in one case and impaired mental 
status in two cases. 
 
As far as the seroprevalence for Toscana virus is concerned, IgG or IgM were positive in 34/100 
cases (34%), with a clear trend to increase with age: 0% from 16 to 20, 22.1% from 21 to 30, 26.7% 
from 31 to 40, 31.6% from 41 to 50, 25.3% from 51 to 60, 33.3% from 61 to 70, 52.6% above 70. 
Livorno and Massa Carrara areas resulted to have the highest prevalence (80 and 75% respectively). 
 
Figure 3. Toscana virus seroprevalence by age, AOUP, 2012-13 
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Discussion 
Certainly, sample size cannot allow any definitive conclusions. However, an increase in the number 
of cases of viral infections of the CNS and an increase in the proportion of cases receiving an 
etiologic diagnosis were observed in the study period, compared with the previous period. In the 
study period an etiologic diagnosis was made in 63.6% of case, which is higher than that reported 
by others. [16, 17] 
Our effort to increase clinical suspicion and standardize the diagnostic approach might have 
contributed. This result is encouraging and prompts us to provide further efforts in this direction. 
Revision of the algorithm, dissemination meetings, preparation of graphic materials such as posters 
and flow charts, might be considered in the future. 
The fact that an earlier lumbar puncture was associated to a higher probability of detecting viral 
genome in CSF, should prompt us not to delay such a crucial procedure. Clinical relevance of viral 
infections of the CNS justifies an aggressive diagnostic approach. It has been reported that the 
realization of a brain scanner before the lumbar puncture was associated with a significant delay in 
the realization of the lumbar puncture in the Emergency Unit. [18] This is consistent also with our 
case series, because almost all patients had undergone plain CT scan before lumbar puncture, also 
when no strict indications existed. However, among patients who underwent lumbar puncture 
beyond 72 hours from the onset of symptoms, the delay was mainly due to delay in accessing the 
hospital, that means general practitioners should also be sensitized on the issue. 
Overall, the data of the 2009-2014 period give a picture of the local epidemiology of the viral 
infections of the CNS. 
Our study does not allow to obtain data on incidence. However, also considering that our hospital is 
a referral centre, viral infections of the CNS seem to have a limited impact in our communities. 
Still, we can assume that cases accessing health services are only the most severe ones and many 
more occur with no or mild clinical manifestations. 
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Age of patients ranged from 18 to 85 years but almost half of patients had from 30 to 50 years. 
Notably, mean age of patients having meningitis was 39.3 while mean age of those having 
involvement of brain parenchyma was 63.6, meaning that older patients more often develop severe 
forms. 
Etiology of our case series generally reflects that reported in the literature for adults, with some 
peculiarities. 
VZV resulted the first cause of viral infection of the CNS. Among the 9 patients with VZV 
infection, all but one had signs of encephalitis. Other case series report Enterovirus to be largely the 
first cause of meningitis while HSV-1 and HSV-2 to be the first cause of encephalitis, followed by 
VZV. [19, 16] In 7/9 cases some kind of immunosuppression was revealed. One case of encephalitis 
reported persistent neurocognitive impairment and one case of meningoradiculoneuritis reported 
paraparesis. One case occurred during varicella and 5 in association with zoster. This should remind 
us about the importance of suspecting CNS involvement in such cases, especially in case of 
immunosuppressed or otherwise fragile patients, to refer the case to hospital and/or timely start 
antiviral treatment. The live attenuated vaccine for VZV is very effective in preventing varicella 
and therefore complications of acute disease, including those affecting the CNS. In fact, although 
cases of meningitis as adverse events following vaccination have been described, incidence is low. 
[20] However, impact of vaccination on reactivation and its most severe manifestations has not 
been established. For instance, among 84 children aged 1 month to 18 years, admitted with 
neurological complications of acute disease, including encephalitis, only 4 had been vaccinated. 
[21] Instead, out of 7 children with meningitis or encephalitis, 4 had received at least one dose of 
vaccine. [22] Other cases of CNS infection due to reactivation of vaccine strain have been reported. 
[23, 24, 25] A live attenuated anti-zoster vaccine has been recently proposed and it has been 
reported to reduce reactivation of VZV, expressing as zoster, by 50%. [26] Possible effects of this 
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vaccine on VZV neurological manifestations has not been established. However, cases of VZV 
meningitis following vaccination in elderly have been reported. [27] 
HSV-1 and HSV-2 were responsible of 6 and 2 cases respectively. All patients with HSV-1 
infection had meningoencephalitis, all cases with HSV-2 infection had meningitis, including one 
case of Mollaret syndrome. Out of six cases of HSV-1 infection, two occurred in patients with 
known causes of immunosuppression, namely hypogammaglobulinemia in one case and steroids 
plus methotrexate for rheumatoid arthritis in the other case; additionally, two other patients were 84 
and 85 years old. This is consistent with the existing literature indicating HSV-1 as a typical 
opportunistic infection. Differently, all three patients with HSV-2 infection had no history or 
findings suggestive of immunosupression. Two out of six patients with HSV-1 infection died while 
all the three patients with HSV-2 infection fully recovered. These data confirm HSV-1 and HSV-2 
to cause different kinds of involvement of the CNS, with different clinical manifestations and 
outcome. Treatment of HSV-1 and HSV-2 traditionally relies on acyclovir, since its introduction 
more than 30 years ago. Resistant strains have been described, but susceptibility tests are not 
routinely performed, since they are not standardized, time-demanding and their clinical relevance 
not established. [28] Acyclovir has also been variously prescribed for primary or secondary 
prophylaxis, but emergence of resistance has been described. [29] 
Toscana virus resulted the second cause of viral infection of the CNS in our case series, together 
with HSV-1. All cases occurred during summer season, consistently with the presence of the vector 
sand-fly. Four cases had meningitis and two cases meningoencephalitis. These data confirm 
Toscana virus to be an emerging infection in the Mediterranean area, including our area. Three out 
of six patients were not born in Italy. Although figures are too little to allow any conclusion, we can 
speculate that possibly Toscana virus is more likely to induce severe clinical manifestations in non-
immune adults and that it is probably quite spread in our communities. Many case reports in 
travelers and clinical research and epidemiologic studies conducted around the Mediterranean 
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region have shown that Toscana virus has a tropism for the CNS and is a major cause of meningitis 
and encephalitis in countries in which it circulates. In central Italy, Toscana virus is the most 
frequent cause of meningitis from May to October, far exceeding enteroviruses. For instance, out of 
120 cases of neuroinvasive infections, in Emilia Romagna in 2012, 28.3% of cases had Toscana 
virus antibodies and 79.4% of them were in the acute phase of the infection. [30] In other northern 
Mediterranean countries, TOSV is among the 3 most prevalent viruses associated with meningitis 
during the warm seasons. [31] Only in 1 out of four cases some kind of immunosuppression was 
present; in fact, differently by VZV and HSV-1, Toscana virus is not a typical opportunistic agent. 
In a series of 17 cases reported in France, All patients presented with fever and neurological signs 
were observed such as aseptic meningitis (n = 6), muscular symptoms (n = 3), or encephalitis 
(n = 4). The outcome was always favorable. At the acute stage, IgM were observed in 14/17 
patients, neutralization tests were positive for 3/8 patients, and RT-PCR confirmed Toscana virus 
infections in 5/8 CSF specimens. [32] Although Toscana virus infection is usually mild, severe 
encephalitis cases have been reported. [33] 
No treatment options are currently available. A study on prevention from infection by Toscana virus 
reported that a combination of recombinant Toscana virus structural proteins N-Gc, used as a 
vaccine, protected 100% of mice infected with a lethal, neurovirulent strain of Toscana virus. [34] 
Other than prevention and antiviral therapy, repellents and insecticides are the principal options to 
reduce the spread of sandfly-borne diseases. Spraying campaigns are usually focused on inhabited 
areas and thus efficient against anthoponotic sandflies, such as P. papatasi. The efficacy is much 
lower against non-anthoponotic sandflies, such as those belonging to the Laroussius subgroup. 
However, without precise mapping of sandfly habitats and breeding areas, insecticide spraying is 
likely to be poorly effective. Because so little is known about natural breeding sites of sandflies, the 
preimaginal stages are rarely targeted by control measures. In campaigns against the adult sandflies, 
assessments of efficacy and cost/benefit are difficult to make because there are few properly 
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controlled studies, and the results of different interventions are seldom compared. Insecticide 
spraying significantly decreases the incidence of Phlebotomus-transmitted diseases only if spraying 
is continuous; sporadic campaigns are considered to be ineffective. Several properties of the 
sandfly-borne phleboviruses make them good candidates for further emergence as human 
pathogens. Because the geographic distribution of these agents is dictated by the distribution of 
their vectors, climate change can modulate at-risk areas and human populations. The high rate of 
mutation of these viruses due to the lack of proofreading activity of the viral RNA polymerase 
generates quasispecies populations, a situation favoring the selection of variants with modified 
phenotypes, potentially including increased virulence and/or transmission efficiency. The 
propensity for genetic reassortment or recombination under conditions of mixed infections may 
result in recombinant viruses with significantly altered pathogenicity characteristics, as has been 
observed with other genera in the Bunyaviridae family.  [35, 36] By definition all arboviruses have 
the capacity to infect and replicate in both vertebrates and invertebrates. Thus, arboviruses have 
evolved the capability of infecting widely different hosts that present very distinct biochemical 
challenges. This “plasticity” in their life cycles increases their capacity to cross species barriers, an 
essential requirement for virus emergence. [37] 
Enterovirus were responsible for one case of meningitis, one of meningoencephalitis and one of 
myelitis. All patients were immunocompetent and all of them fully recovered, consistently with the 
existing literature. 
Two patients had West Nile virus IgM in the study period, consistently with the definition of 
probable case established by the European Centers for Disease Control. One patient had meningitis 
and one myelitis. Both occurred in immunocompetent patients. Human cases of WNV-associated 
fever and/or neurological disorders have been reported in Italy since 2008. The first outbreak 
occurred in the northeastern region of Italy surrounding the Po River and was caused by the Po 
River lineage 1 strain, and since then, WNV infections have been reported in several regions of 
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central Italy. Although the virus is highly genetically conserved, stochastic mutations in its genome 
may lead to the emergence of new strains, as was observed in Italy in 2011 with the identification of 
two new lineage 1 strains, the WNV Piave and WNV Livenza strains. [38] Confirmed human cases 
have been reported in Puglia, Lombardia, Veneto, Emilia Romagna and Sardinia Italian regions. 
[39] West Nile virus transmission has been confirmed in the last four years in Europe and in the 
Mediterranean Basin. An increasing concern towards West Nile disease has been observed due to 
the high number of human and animal cases reported in these areas confirming the importance of 
this zoonosis. A new epidemiological scenario is currently emerging: although new introductions of 
the virus from abroad are always possible, confirming the epidemiological role played by migratory 
birds, the infection endemisation in some European territories today is a reality supported by the 
constant reoccurrence of the same strains across years in the same geographical areas. Despite the 
WND reoccurrence in the Old World, the overwintering mechanisms are not well known, and the 
role of local resident birds or mosquitoes in this context is poorly understood. A recent new 
epidemiological scenario is the spread of lineage 2 strain across European and Mediterranean 
countries in regions where lineage 1 strain is still circulating creating favourable conditions for 
genetic reassortments and emergence of new strains. [40] 
In case symptoms of cerebral parenchyma involvement are present, VZV and HSV-1 were the most 
frequent etiology and should be considered in such a case; in case of pure meningitis, Toscana virus 
and HSV-2 were the most frequent etiology and should be considered in such a case. 
Plain CT scan is not able to detect signs of meningitis or encephalitis and it can only be useful in 
ruling out contraindications to lumbar puncture. We believe at least in cases signs of encephalitis 
are evident at presentation magnetic resonance should be considered as first line examination. 
EEG confirms its role in the diagnosis and follow up of CNS infections. 
An increased WBC count, particularly neutrophils, was present at admission in a relevant number of 
cases, and no concomitant bacterial infection was detected, meaning that this cannot be used as a 
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criterion to discriminate between bacterial and viral infection of the CSF. On the opposite, 
procalcitonin seems to confirm its correlation with bacterial etiology. 
An increased WBC count in CSF, usually lymphocytes, was present in almost all cases, confirming 
this to be a criterion to confirm or rule out meningitis. CSF/blood glucose level, more than absolute 
CSF glucose level, is a highly sensitive parameter to distinguish between aseptic and bacterial 
meningitis, also in line with recent reports. [41] 
The fact that Enterovirus induced a mild inflammatory reaction in terms of leukocytes, is consistent 
with what already reported. [19] What is quite noteworthy is the significantly stronger inflammatory 
response, both in terms of leukocytes and proteins, induced by VZV in comparison with other 
etiologies in our case series. 
The results of the seroprevalence survey confirm Toscana virus to be widely spread in our area. A 
wider seroprevalence survey conducted in the area of Siena found 19.8% of adults to be immunized 
against Toscana virus, with an age-dependent trend. [42] Other data indicate a seroprevalence of 
Toscana virus of 77.2% in the forestry workers of the Tuscany region. This fact is strictly correlated 
with the ecological niches specific for the survival of Toscana virus arthropod vector. [43]  
Climate changes might impact on vectors activity and spread of emerging infections such as West 
Nile and Toscana virus infection. 
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Conclusions 
Standardization of the diagnostic approach to CNS viral infection may contribute to increase case-
finding and etiologic diagnosis. 
VZV and HSV are the most common cause of CNS viral infection in our setting and are frequently 
responsible of cerebral parenchyma involvement. Toscana virus and West Nile are emerging 
infections also in our area. 
An early lumbar puncture is necessary to increase the probability of obtaining an etiologic 
diagnosis. High levels of WBC and proteins in CSF are suggestive of VZV infection. 
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PhD, Work Experience 
Attended conferences: 
1. 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 
March 31 - April 2, 2012; London, United Kingdom.  
2. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012). 
September 9-12, 2012, San Francisco. 
3. 53rd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2013). 
September 10-13, 2013 Denver. 
4. 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2014). 
September 5-9, 2014, Washington DC. 
Presentations at conferences: 
 On October 2012 presentation titled Cardiac Implantable Electronic Devices (CIED) 
infections: a challenge for today and tomorrow at the symposyum Early Recognition and 
Management of Life-Threatening Infections at the Brighton and Sussex Medical School of 
Brighton. 
 Presentations at the following conferences: 
 Focus on difficult-to-treat infections. Pisa, 27-28 settembre 2012. 
 Attualità sulle Infezioni Correlate all’Assistenza. Seminario SIMIT.Lucca, 24 ottobre 
2012.  
 Medicina Perioperatoria. Lab 2012. Pisa, 5-7 dicembre 2012. 
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 Le infezioni dei dispositivi cardiovascolari impiantabili: una problematica crescente. 
Bari, 1 marzo 2013. 
 IV Corso di Aggiornamento Interdisciplinare sul Paziente Critico. Matera, 11-12 aprile 
2013. 
 XIII Giornata Infettivologica Toscana. Pisa, 21 maggio 2013. 
 Tuscany Critical Care Group. XVI Annual Meeting. Firenze, 29-31 maggio 2014. 
 XVII Congresso Regionale FADOI. Firenze, 25-26 ottobre 2013. 
 Convegno su assistenza e gestione del paziente di difficile svezzamento. Volterra (PI), 
27 settembre 2013. 
 Focus on difficult-to-treat infections. Pisa, 7-8 ottobre 2013. 
 Infezioni Emergenti in Medicina Interna: Problematiche Regionali, Obiettivi clinici e 
verifiche di appropriatezza. Firenze, 15 novembre 2013. 
 Focus on HIV e epatite. Pisa, 18 novembre 2013. 
 Il ruolo del Medico di Medicina Generale nella gestione del paziente luetico. Calcinaia 
(PI), 18 dicembre 2013. 
 La riscossa dei nuovi betalattamici. Pisa, 10 dicembre 2013. 
 Seminari di Cardiochirurgia. Le patologie della tricuspide. Pisa, 7 febbraio 2014. 
 Focus on Infezioni fungine in Medicina Interna. Pisa, 11 marzo 2014. 
 Osteomyelitis in diabetic foot: medical and surgical treatment. Firenze, 11-12 aprile 
2014. 
 Società Italiana di Terapia Antiinfettiva. V Congresso Nazionale, 16 settembre 2014. 
 Focus on difficult-to-treat infections. Pisa, 6-7 ottobre 2014. 
 Focus on HIV ed epatite. Pisa, 17-19 novembre 2014. 
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 On October 2013 lessons on treatment of community and hospital acquired pneumonia and 
pneumonia in the immunocompromised host at the Specialty of Pneumology of Pisa 
Universit 
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1. Microbiology of cardiac implantable electronic device infections. 
Europace. 2012 Sep;14(9):1334-9. (IF 3.05) 
2. Cardiovascular implantable electronic device endocarditis treated with daptomycin with 
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3. Susceptibility of Streptococcus pneumoniae clinical isolates to quinolones. 
Journal of Chemotherapy. Vol. 24 (2012) - pp. 185,186. (IF 1.073) 
4. Comparison of teicoplanin an vancomycin in vitro activity on clinical isolates of 
Staphylococcus aureus. 
Journal of Chemotherapy. Vol. 24 (2012) - pp. 187-190. (IF 1.073) 
5. Antimicrobial resistance in Internal Medicine Wards. 
Internal and Emergency Medicine. 2012; 7 (Suppl 3):S271–S281 (IF 2.41) 
6. Micafungin for C. albicans  pacemaker-associated endocarditis: a case report and review 
of the literature. Mycopathologia. 2012 Oct 17. (IF 1.545) 
7. Daptomycin concentrations in valve tissues and vegetations in bacterial endocarditis. 
Antimicrobial Agents and Chemotherapy. 2012 Oct 22. (IF 4.451) 
8. Synergistic Activity of Colistin plus Rifampin against Colistin-Resistant KPC-producing 
Klebsiella pneumoniae. 
Antimicrob Agents Chemother. 2013 Aug;57(8):3990-3. (IF 4.451) 
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9. Epidemiology and outcome of Klebsiella pneumoniae carbapenemase-producing 
Klebsiella pneumoniae in a tertiary level Cardiac Intensive Care Unit. 
Minerva Anestesiol. 2013 Nov 26. (IF 2.272) 
10. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella 
pneumoniae infections: the relevance of concomitant systemic antibiotic therapy. 
Antimicrob Agents Chemother. 2014 Jan 13. (IF 4.451) 
11. Hepatic Abscess Caused by Trans-Gastric Migration of a Fishbone. 
Surg Infect (Larchmt). 2014 May 9. (IF 1.721) 
 
Other publications: 
1. Un nemico chiamato Klebsiella. 
Sole 24 ore Sanità Toscana. 24-30 gennaio 2012. 
2. L’epidemia da Klebsiella pneumoniae produttrice di carbapenemasi. Una sfida per il sistema 
sanitario della Toscana. 
Toscana Medica 8/12 
3. Management of invasive fungal infections in non-neutropenic patients. 
HAART, HIV correlated pathologies and other infections. 2012, n. 17. 
4. Le echinocandine nel trattamento delle candidemie 
Reviews in Health Care. 2013; 4 (suppl. 2): 5-12. 
5. Appropriateness and cost-effectiveness in the treatment of invasive candidiasis in Internal 
Medicina Wards. 
Italian Journal of Medicine 2014; volume 8:221-224. 
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Poster at conferences: 
1. Atrium blood culture for the diagnosis of cardiovascular implantable electronic device 
(CIED) endocarditis.  
Poster alla XXII edizione dello European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID), Londra, 31 marzo-3 aprile 2012. 
2. Epidemiological, microbiological and clinical characteristics of an outbreak of colistin-
resistant KPC carbapenemase-producing Klebsiella pneumoniae. 
Poster alla XXII edizione dello European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID), Londra, 31 marzo-3 aprile 2012. 
3. Microbiology of cardiac implantable electronic device infections. 
Poster alla XXII edizione dello European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID), Londra, 31 marzo-3 aprile 2012. 
4. Emergence of a colistin-resistant KPC-3-producing Klebsiella pneumoniae ST512 clone 
in an Italian university hospital. 
Presentazione orale alla XXII edizione dello European Congress of Clinical 
Microbiology and Infectious Diseases (ECCMID), Londra, 31 marzo-3 aprile 2012. 
5. Synergistic Activity of Colistin (COL) plus Rifampin (RIF) Against COL-Resistant (R) 
and Susceptible (S) KPC-producing Klebsiella pneumoniae (KPC-KP) clinical isolates  
Poster alla 52a edizione della Interscience Conference on Antimicrobial Agents and 
Chemotherapy, San Francisco, 9-12 settembre 2012. 
6. Colistin-heteroresistance in Klebsiella pneumoniae carbapenemase (KPC)-producing 
Klebsiella pneumoniae: from inducible resistance to stable resistance. 
Poster alla XXIII edizione dello European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID), Berlino, 27-30 aprile 2012. 
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7. Clinical experience with daptomycin treatment of osteomyelitis: 6-year retrospective 
analysis from the EU-COREˆSM registry. 
Poster alla XXIII edizione dello European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID), Berlino, 27-30 aprile 2012. 
8. Clinical Risk of Klebsiella pneumoniae carbapenemase (KPC)-Klebsiella pneumoniae 
(KPC-Kp) donor-derived disease in transplant recipients: the experience at a tertiary 
teaching hospital in Italy. 
Poster alla XXIII edizione dello European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID), Berlino, 27-30 aprile 2012. 
9. Microbiological diagnosis of cardiac device-related infections: comparison between 
prolonged cultures and sample cultures after sonication. 
Poster alla XXIII edizione dello European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID), Berlino, 27-30 aprile 2012. 
10. Gut decontamination of Klebsiella pneumoniae carbapenemase (KPC)-producing 
Klebsiella pneumoniae carriers with oral gentamicin in patients with or without 
concomitant systemic antibiotic therapy. 
Abstract alla XXIII edizione dello European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID), Berlino, 27-30 aprile 2012. 
11. Synergistic activity of colistin plus rifampin against strains of colistin-resistant and 
colistin-susceptible Klebsiella pneumoniae carbapenemase (KPC)-producing Klebsiella 
pneumoniae 
Abstract alla XXIII edizione dello European Congress of Clinical Microbiology and 
Infectious Diseases (ECCMID), Berlino, 27-30 aprile 2012. 
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Publications on science blogs: 
 Since 2013 collaboration with the blog CORIST (COntrollo del Rischio Infettivo in Sanità 
in Toscana) of Azienda Regionale di Sanità della Toscana: 
1. Il consumo di antibiotici negli ospedali della Toscana. 
Il giornale del CORIST (COntrollo del Rischio Infettivo in Sanità in Toscana). Azienda 
Regionale Sanità Toscana. 2014. 
2. Infezioni correlate all’assistenza, uso di antibiotici e resistente batteriche: una sfida per 
l’Italia. 
Il giornale del CORIST (COntrollo del Rischio Infettivo in Sanità in Toscana). Azienda 
Regionale Sanità Toscana. 2014. 
3. Antimicrobial stewardship: perché no. 
Il giornale del CORIST (COntrollo del Rischio Infettivo in Sanità in Toscana). Azienda 
Regionale Sanità Toscana. 2014. 
4. Ebola: il punto sull’epidemia. 
Il giornale del CORIST (COntrollo del Rischio Infettivo in Sanità in Toscana). Azienda 
Regionale Sanità Toscana. 2014. 
5. Ebola: aggiornamento 
Il giornale del CORIST (COntrollo del Rischio Infettivo in Sanità in Toscana). Azienda 
Regionale Sanità Toscana. 2014. 
 
 Since 2009 collaboration with the blog Salute Internazionale: 
1. Il controllo globale della tubercolosi 
www.saluteinternazionale.info. 19 gennaio 2012. 
2. Il controllo globale della malaria: buone e cattive notizie. 
www.saluteinternazionale.info. 23 febbraio 2012. 
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3. Infezioni emergenti e riemergenti. 
www.saluteinternazionale.info. 30 maggio 2012. 
4. Un mondo senza AIDS è possibile? 
www.saluteinternazionale.info. 15 ottobre 2012. 
5. Guerra alla droga e HIV 
www.saluteinternazionale.info. 29 ottobre 2012. 
6. Il controllo globale della tubercolosi: risultati, opportunità, rischi per il futuro. 
www.saluteinternazionale.info. 3 dicembre 2012. 
7. Task shifting. L’arte (e la necessità) della delega. 
www.saluteinternazionale.info. 18 marzo 2013. 
8. L’eredità della SARS: sorveglianza e controllo delle epidemie all’età della 
globalizzazione.  
www.saluteinternazionale.info. 18 aprile 2013. 
9. Bolsa Familia: come il Brasile ha ridotto la mortalità infantile. 
www.saluteinternazionale.info. 18 luglio 2013. 
10. Guerra alla droga ed epatite C. 
www.saluteinternazionale.info. 28 ottobre 2013. 
11. Guerra e salute: la poliomielite in Siria 
www.saluteinternazionale.info. 18 novembre 2013. 
12. Crisi economica e HIV: il caso della Grecia 
www.saluteinternazionale.info. 12 marzo 2014. 
13. Ebola! Ancora epidemia. 
www.saluteinternazionale.info. 14 aprile 2014. 
14. HIV in Italia: un nemico tutt’altro che sconfitto. 
www.saluteinternazionale.info 3 dicembre 2014. 
